Avectas, ONK to develop cancer cell therapy

By The Science Advisory Board staff writers

May 6, 2020 -- Avectas has exclusively licensed a chimeric antigen receptor-directed natural killer cell therapy (CAR NK) from ONK Therapeutics for the treatment of B-cell malignancies such as non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

The partnership aims to develop a chimeric antigen receptor that uses natural killer cells that are engineered to target specific cancer cells and increase therapeutic potency by adding a secondary cancer cell-killing mechanism using ONK's death receptor (DR5) TRAIL variant. If successful, the off-the-shelf allogeneic therapy would provide transient cell-killing effects in a dose-controlled manner.

Under the collaboration, ONK will accelerate the development of the therapy, incorporating its DR5 TRAIL variant, to a phase I clinical trial. Avectas will engineer the therapy using its nonviral cell engineering platform. Avectas will retain worldwide development and commercialization rights to the therapy.

Avectas nets patent for cell engineering technology
Avectas has received a patent for its Solupore cell engineering technology.
Vycellix, Avectas partner for product development
Vycellix and Avectas have unveiled plans to collaborate on the development of cell-based immunotherapeutic products.

Copyright © 2020 scienceboard.net


Conferences
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter